Article info
Points to consider
EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology
- Correspondence to William G Dixon, Arthritis Research UK Epidemiology Unit, The University of Manchester, Stopford Building, Oxford Road, Manchester M13 9PT, UK; will.dixon{at}manchester.ac.uk
Citation
EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology
Publication history
- Accepted February 6, 2010
- First published June 4, 2010.
Online issue publication
August 10, 2010
Article Versions
- Previous version (4 June 2010).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions